NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

乳癌:競爭情形 (2020年)

Breast Cancer - Competitive Landscape in 2020

出版商 GlobalData 商品編碼 995611
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
乳癌:競爭情形 (2020年) Breast Cancer - Competitive Landscape in 2020
出版日期: 2020年10月30日內容資訊: 英文 57 Pages
簡介

乳癌的治療藥的開發平台醫藥品,現在有1687種產品在臨床實驗中,其中的319種以HER-2 (人類表皮生長因子受體2)為標的。疾病的發病率上升預期促進市場,不過,部分品牌藥的專利到期對今後的市場來說成為的威脅。

本報告提供乳癌治療藥的開發、上市趨勢預測相關分析,目前治療環境,及主要成藥、開發平台醫藥品的概要,臨床實驗的進展,各種產品的上市可能性,社群媒體和數位行銷的活用狀況,主要企業的產品開發、策略展開的動向等資訊彙整,為您概述為以下內容。

目錄

第1章 目錄

第2章 摘要整理

第3章 簡介

  • 分析範圍
  • 流行病學概要
  • 流行病學

第4章 成藥的評估

  • 成藥概要
  • 成藥的簡介

第5章 開發平台醫藥品的評估

  • 開發平台醫藥品概要
  • 開發平台醫藥品:各地區的明細
  • 開發平台醫藥品:各分子類型、各標的的明細
  • 優先的審查的指定的可能性
  • 相變的成功率
  • 核準的可能性

第6章 臨床實驗的評估

  • 臨床實驗概要:各相 (各期)
  • 各地區的概要
  • 各治療領域的展望
  • 主要贊助商 (資金提供者)
  • 登記情形分析
  • 實行可能性分析

第7章 商業性評估

  • 今後的市場促進因素

第8章 社群媒體與數位行銷

  • Twitter的有力Chatter
  • 知名品牌藥企業的網站
  • 信任來源和引用來源

第9章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC031CL

GlobalData's "Breast Cancer - Competitive Landscape in 2020" combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Human epidermal growth factor receptor 2 (HER-2) targeting drugs are the major focus of drug developers. There are 1687 drugs in the pipeline, 319 of which targets HER-2. Big pharma dominates R&D in this indication, with Roche, Novartis, Pfizer, AstraZeneca, and Eli Lilly leading the way. Increasing incidence expected to drive growth in breast cancer market, but patent expiry of several branded therapies poses a threat to the breast cancer space.

This reports provides a data-driven overview of the current and future competitive landscape in breast cancer therapeutics.

Scope

Components of the report include -

  • Disease epidemiology
  • Marketed drugs assessment
  • Pipeline drugs assessment
  • Clinical trials assessment
  • Commercial assessment
  • Social media overview
  • Digital marketing overview

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global breast cancer market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global breast cancer market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1.Table of Contents

  • 1.1 Preface
  • 1.2 Abbreviations
  • 1.3 Related Reports
  • 1.4 Upcoming Related Reports

2 Executive Summary

  • 2.1 Key Findings
  • 2.2 Key Events

3 Introduction

  • 3.1 Report Scope
  • 3.2 Disease Overview Epidemiology Overview
  • 3.3 Epidemiology

4 Marketed Drugs Assessment

  • 4.1 Marketed Drugs Overview
  • 4.2 Marketed Drug Profiles

5 Pipeline Assessment

  • 5.1 Pipeline Overview
  • 5.2 Pipeline Breakdown by Region
  • 5.3 Pipeline Breakdown by Molecule Type and Target
  • 5.4 Drug Review Designations
  • 5.5 Phase Transition Success Rates
  • 5.6 Likelihood of Approval

6 Clinical Trial Assessment

  • 6.1 Clinical Trials Overview by Phase
  • 6.2 Overview by Region
  • 6.4 Therapy Area Perspective
  • 6.4 Leading Sponsors
  • 6.5 Enrollment Analytics
  • 6.6 Feasibility Analysis

7 Commercial Assessment

  • 7.1 Upcoming Market Catalysts

8 Social Media and Digital Marketing

  • 8.1 Key Twitter Chatter
  • 8.2 Top Branded Websites
  • 8.3 Trust Flow and Citation Flow

9 Appendix

  • 9.1 Methodology
  • 9.2 About the Authors
  • 9.3 About GlobalData
  • 9.4 Contact Us
  • 9.5 Disclaimer